Zobrazeno 1 - 10
of 50
pro vyhledávání: '"RET receptor tyrosine kinase"'
Autor:
Song Yi Bae, Hannah E. Bergom, Abderrahman Day, Joseph T. Greene, Zoi E. Sychev, Gabrianne Larson, Eva Corey, Stephen R. Plymate, Tanya S. Freedman, Justin H. Hwang, Justin M. Drake
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results i
Externí odkaz:
https://doaj.org/article/3e48ddb167a545a593cf9fd00b156061
Autor:
Arun Kumar Mahato, Yulia Sidorova
Publikováno v:
Cell and Tissue Research
Rearranged during transfection (RET), in complex with glial cell line-derived (GDNF) family receptor alpha (GFRα), is the canonical signaling receptor for GDNF family ligands (GFLs) expressed in both central and peripheral parts of the nervous syste
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Bulletin of the Korean Chemical Society. 40:207-213
Autor:
Mahato, Arun Kumar, Sidorova, Yulia A.
Rearranged during transfection (RET), in complex with glial cell line-derived (GDNF) family receptor alpha (GFR alpha), is the canonical signaling receptor for GDNF family ligands (GFLs) expressed in both central and peripheral parts of the nervous s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1593::4eb8b05ce8bb446c9825908444214283
http://hdl.handle.net/10138/320367
http://hdl.handle.net/10138/320367
Publikováno v:
Baillie`re's best practice and research in clinical endocrinology and metabolism (Online) 31 (2017): 307–318. doi:10.1016/j.beem.2017.04.013
info:cnr-pdr/source/autori:De Falco V.; Carlomagno F.; Li H.-Y.; Santoro M./titolo:The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer/doi:10.1016%2Fj.beem.2017.04.013/rivista:Baillie`re's best practice and research in clinical endocrinology and metabolism (Online)/anno:2017/pagina_da:307/pagina_a:318/intervallo_pagine:307–318/volume:31
info:cnr-pdr/source/autori:De Falco V.; Carlomagno F.; Li H.-Y.; Santoro M./titolo:The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer/doi:10.1016%2Fj.beem.2017.04.013/rivista:Baillie`re's best practice and research in clinical endocrinology and metabolism (Online)/anno:2017/pagina_da:307/pagina_a:318/intervallo_pagine:307–318/volume:31
RET receptor tyrosine kinase (RTK) acts as an ontogenetic driver in several human malignancies, including papillary and medullary thyroid carcinoma, lung adenocarcinoma, colorectal carcinoma, Spitzoid neoplasms, salivary gland carcinoma and chronic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f7c05bd5f0866c7bb2f7f8a127b177
http://hdl.handle.net/11588/703845
http://hdl.handle.net/11588/703845
Autor:
John Russell, Meenakshi Rao, Svetlana L. Sabel, Daniella Rastelli, Sanjay Kumar, Michael D. Gershon
Publikováno v:
Gastroenterology. 150:S344-S345
Autor:
Laura Cerchia, Jocelyne Boulay, Domenico Libri, Karine Gombert, Vittorio de Franciscis, Bertrand Tavitian, Carine Pestourie, Frédéric Ducongé, Youssef Aissouni
Publikováno v:
PLOS Biology. 13:e1002215
The authors and editors retract this publication following an investigation into concerns around the data presented in Figures 3 and 4 that were brought to the editors’ attention. The text below has been agreed to by the editors and authors. Some o